Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
26
03
2023
accepted:
16
11
2023
medline:
22
11
2023
pubmed:
21
11
2023
entrez:
21
11
2023
Statut:
epublish
Résumé
Not all patients with ulcerative colitis (UC) respond initially to treatment with biologic agents, and predicting their efficacy prior to treatment is difficult. Vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 (α4β7) integrin, suppresses immune cell migration by blocking the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule 1. Reports about histological features that predict vedolizumab efficacy are scarce. So, we examined the association between histological features and vedolizumab efficacy. This was a multicenter, retrospective study of patients with UC treated with vedolizumab. Biopsy specimens taken from the colonic mucosa prior to vedolizumab induction were used, and the areas positively stained for CD4, CD68, and CD45 were calculated. Clinical and histological features were compared between those with and without remission at week 22, and the factors associated with clinical outcomes were identified. We enrolled 42 patients. Patients with a high CD4+ infiltration showed a better response to vedolizumab [odds ratio (OR) = 1.44, P = 0.014]. The concomitant use of corticosteroids and high Mayo scores had a negative association with the vedolizumab response (OR = 0.11, P = 0.008 and OR = 0.50, P = 0.009, respectively). Histological evaluation for CD4+ cell infiltration may be helpful in selecting patients who can benefit from vedolizumab.
Identifiants
pubmed: 37985889
doi: 10.1038/s41598-023-47618-3
pii: 10.1038/s41598-023-47618-3
pmc: PMC10662207
doi:
Substances chimiques
vedolizumab
9RV78Q2002
Gastrointestinal Agents
0
Integrins
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20262Informations de copyright
© 2023. The Author(s).
Références
J Crohns Colitis. 2020 Jun 19;14(5):694-709
pubmed: 31777929
Gastroenterology. 2012 Feb;142(2):257-65.e1-3
pubmed: 22062358
Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5
pubmed: 23735746
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Aliment Pharmacol Ther. 2001 Aug;15(8):1211-8
pubmed: 11472325
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
Nat Rev Immunol. 2014 May;14(5):329-42
pubmed: 24751956
PLoS One. 2017 Oct 5;12(10):e0186142
pubmed: 28982144
J Crohns Colitis. 2019 Oct 28;13(11):1450-1458
pubmed: 30946450
Inflamm Bowel Dis. 2012 Nov;18(11):2107-19
pubmed: 22419649
J Immunol. 1997 May 15;158(10):5007-16
pubmed: 9144521
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75
pubmed: 19509315
Inflamm Bowel Dis. 2020 Jul 17;26(8):1232-1238
pubmed: 31633167
J Crohns Colitis. 2022 Jan 28;16(1):2-17
pubmed: 34635919
Inflamm Bowel Dis. 2015 Dec;21(12):2879-85
pubmed: 26288002
Nature. 2015 Jan 15;517(7534):293-301
pubmed: 25592534
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Front Immunol. 2020 Aug 27;11:1847
pubmed: 32983101
Gut. 2017 Jan;66(1):50-58
pubmed: 26475633
Am J Gastroenterol. 2018 Sep;113(9):1345
pubmed: 29946178
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2
pubmed: 26917043
Inflamm Bowel Dis. 2017 Mar;23(3):404-408
pubmed: 28178003
Scand J Gastroenterol. 2007 Nov;42(11):1312-20
pubmed: 17852866
Lancet. 2012 Nov 3;380(9853):1606-19
pubmed: 22914296
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2019 Sep 26;381(13):1201-1214
pubmed: 31553833
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095